News & Events about Ultragenyx Pharmaceutical Inc.
Deutsche Bank AG grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE Get Rating) by 3.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 861,679 shares of the biopharmaceutical companys stock after purchasing an ...
Globe Newswire
5 months ago
Huang brings decades of expertise to MassBio Board to aid in organizational mission
Dennis Huang - Ultragenyx
Dennis Huang, chief technical operations officer and executive vice president of gene therapy at Ultragenyx has been named to the board of directors for MassBio
BEDFORD, Mass., April 28...
Cantor Fitzgerald initiated coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE Get Rating) in a report released on Wednesday morning, The Fly reports. The firm issued an overweight rating and a $114.00 price objective on the biopharmaceutical companys stock. A number of other analysts have...
Globe Newswire
6 months ago
NOVATO, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an ...
Globe Newswire
6 months ago
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company
Eric Crombez, M.D.
Eric Crombez, M.D.
NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief ...